{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:09:16Z","timestamp":1788408556955,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T00:00:00Z","timestamp":1448409600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12876-015-0389-9","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T06:41:30Z","timestamp":1448433690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Albumin treatment regimen for type 1 hepatorenal syndrome: a dose\u2013response meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Francesco","family":"Salerno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta J.","family":"Navickis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahlon M.","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,25]]},"reference":[{"key":"389_CR1","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jhep.2011.03.012","volume":"55","author":"F Salerno","year":"2011","unstructured":"Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice. J Hepatol. 2011;55:1241\u20138.","journal-title":"J Hepatol"},{"key":"389_CR2","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","volume":"362","author":"P Gin\u00e8s","year":"2003","unstructured":"Gin\u00e8s P, Guevara M, Arroyo V, Rod\u00e9s J. Hepatorenal syndrome. Lancet. 2003;362:1819\u201327.","journal-title":"Lancet"},{"key":"389_CR3","first-page":"1310","volume":"56","author":"F Salerno","year":"2007","unstructured":"Salerno F, Gerbes A, Gin\u00e8s P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310\u20138.","journal-title":"Gut"},{"key":"389_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hep.26359","volume":"57","author":"BA Runyon","year":"2013","unstructured":"Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology. 2013;57:1\u201327.","journal-title":"Hepatology"},{"key":"389_CR5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/oxfordjournals.aje.a116237","volume":"135","author":"S Greenland","year":"1992","unstructured":"Greenland S, Longnecker MP. Methods for trend estimation from summarized dose\u2013response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301\u20139.","journal-title":"Am J Epidemiol"},{"key":"389_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010;137:21\u201330.","journal-title":"Clin Immunol"},{"key":"389_CR7","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008\u201312.","journal-title":"JAMA"},{"key":"389_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/aje\/kwm189","volume":"166","author":"I Shrier","year":"2007","unstructured":"Shrier I, Boivin JF, Steele RJ, Platt RW, Furlan A, Kakuma R, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol. 2007;166:1203\u20139.","journal-title":"Am J Epidemiol"},{"key":"389_CR9","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","volume":"342","author":"J Concato","year":"2000","unstructured":"Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887\u201392.","journal-title":"N Engl J Med"},{"key":"389_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00198-009-0991-1","volume":"21","author":"MM Wilkes","year":"2010","unstructured":"Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant\/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int. 2010;21:679\u201388.","journal-title":"Osteoporos Int"},{"key":"389_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040078","volume":"4","author":"D Moher","year":"2007","unstructured":"Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG. Epidemiology and reporting characteristics of systematic reviews. PLoS Med. 2007;4, e78.","journal-title":"PLoS Med"},{"key":"389_CR12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"389_CR13","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/hep.510290629","volume":"29","author":"P Angeli","year":"1999","unstructured":"Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690\u20137.","journal-title":"Hepatology"},{"key":"389_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","volume":"33","author":"J Uriz","year":"2000","unstructured":"Uriz J, Gin\u00e8s P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000;33:43\u20138.","journal-title":"J Hepatol"},{"key":"389_CR15","first-page":"15","volume":"64","author":"J-P Mulkay","year":"2001","unstructured":"Mulkay J-P, Louis H, Donckier V, Bourgeois N, Adler M, Devi\u00e8re J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg. 2001;64:15\u20139.","journal-title":"Acta Gastroenterol Belg"},{"key":"389_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1053\/gast.2002.32364","volume":"122","author":"R Moreau","year":"2002","unstructured":"Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Icha\u00ef P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923\u201330.","journal-title":"Gastroenterology"},{"key":"389_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hep.20262","volume":"40","author":"F Wong","year":"2004","unstructured":"Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55\u201364.","journal-title":"Hepatology"},{"key":"389_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","volume":"47","author":"C Alessandria","year":"2007","unstructured":"Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47:499\u2013505.","journal-title":"J Hepatol"},{"key":"389_CR19","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","volume":"134","author":"M Mart\u00edn-Llah\u00ed","year":"2008","unstructured":"Mart\u00edn-Llah\u00ed M, P\u00e9pin MN, Guevara M, D\u00edaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352\u20139.","journal-title":"Gastroenterology"},{"key":"389_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","volume":"53","author":"S Neri","year":"2008","unstructured":"Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830\u20135.","journal-title":"Dig Dis Sci"},{"key":"389_CR21","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","volume":"134","author":"AJ Sanyal","year":"2008","unstructured":"Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360\u20138.","journal-title":"Gastroenterology"},{"key":"389_CR22","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","volume":"103","author":"P Sharma","year":"2008","unstructured":"Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103:1689\u201397.","journal-title":"Am J Gastroenterol"},{"key":"389_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1665-2681(19)31767-3","volume":"8","author":"LE Mu\u00f1oz","year":"2009","unstructured":"Mu\u00f1oz LE, Alcal\u00e1 EG, Cordero P, Mart\u00ednez MA, V\u00e1zquez NY, Galindo S, et al. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico. Ann Hepatol. 2009;8:207\u201311.","journal-title":"Ann Hepatol"},{"key":"389_CR24","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/MCG.0b013e318188947c","volume":"43","author":"C Skagen","year":"2009","unstructured":"Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 2009;43:680\u20135.","journal-title":"J Clin Gastroenterol"},{"key":"389_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/s-0028-1109084","volume":"47","author":"V Kalckreuth von","year":"2009","unstructured":"von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study. Z Gastroenterol. 2009;47:21\u20136.","journal-title":"Z Gastroenterol"},{"issue":"Suppl 1","key":"389_CR26","doi-asserted-by":"publisher","first-page":"S332","DOI":"10.1016\/S0168-8278(10)60854-9","volume":"52","author":"M Rivero","year":"2010","unstructured":"Rivero M, Rodr\u00edguez-Gand\u00eda M, Serradilla R, Arranz G, Milicua JM, Ruiz-del-\u00c1rbol L. A prospective comparative study of terlipressin and albumin for type-1 hepatorenal syndrome (HRS) in patients with cirrhosis and spontaneous bacterial peritonitis (SBP) vs cirrhosis alone. J Hepatol. 2010;52 Suppl 1:S332.","journal-title":"J Hepatol"},{"key":"389_CR27","first-page":"1946","volume":"12","author":"FN Silawat","year":"2011","unstructured":"Silawat FN, Shaikh MK, Lohana RK, Devrajani BK, Ali Shah SZ, Ansari A. Efficacy of terlipressin and albumin in the treatment of hepatorenal syndrome. World Appl Sci J. 2011;12:1946\u201350.","journal-title":"World Appl Sci J"},{"key":"389_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00535-011-0485-8","volume":"47","author":"Y Narahara","year":"2012","unstructured":"Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, et al. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol. 2012;47:313\u201320.","journal-title":"J Gastroenterol"},{"key":"389_CR29","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","volume":"56","author":"V Singh","year":"2012","unstructured":"Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study. J Hepatol. 2012;56:1293\u20138.","journal-title":"J Hepatol"},{"key":"389_CR30","first-page":"764","volume":"3","author":"H Tavakkoli","year":"2012","unstructured":"Tavakkoli H, Yazdanpanah K, Mansourian M. Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial. Int J Prev Med. 2012;3:764\u20139.","journal-title":"Int J Prev Med"},{"key":"389_CR31","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","volume":"17","author":"I Colle","year":"2002","unstructured":"Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barri\u00e8re E, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol. 2002;17:882\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"389_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hep.23283","volume":"51","author":"A Nazar","year":"2010","unstructured":"Nazar A, Pereira GH, Guevara M, Mart\u00edn-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51:219\u201326.","journal-title":"Hepatology"},{"key":"389_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2010.11.020","volume":"55","author":"TD Boyer","year":"2011","unstructured":"Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315\u201321.","journal-title":"J Hepatol"},{"key":"389_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hep.510230122","volume":"23","author":"V Arroyo","year":"1996","unstructured":"Arroyo V, Gin\u00e8s P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis, International Ascites Club. Hepatology. 1996;23:164\u201376.","journal-title":"Hepatology"},{"key":"389_CR35","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1365-2036.2006.03086.x","volume":"24","author":"F Fabrizi","year":"2006","unstructured":"Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006;24:935\u201344.","journal-title":"Aliment Pharmacol Ther"},{"key":"389_CR36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/039139880903200303","volume":"32","author":"F Fabrizi","year":"2009","unstructured":"Fabrizi F, Dixit V, Messa P, Martin P. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials. Int J Artif Organs. 2009;32:133\u201340.","journal-title":"Int J Artif Organs"},{"key":"389_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.23286","volume":"51","author":"LL Gluud","year":"2010","unstructured":"Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51:576\u201384.","journal-title":"Hepatology"},{"key":"389_CR38","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1440-1746.2009.06132.x","volume":"25","author":"SV Sagi","year":"2010","unstructured":"Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010;25:880\u20135.","journal-title":"J Gastroenterol Hepatol"},{"key":"389_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11255-010-9725-8","volume":"43","author":"M Dobre","year":"2011","unstructured":"Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol. 2011;43:175\u201384.","journal-title":"Int Urol Nephrol"},{"key":"389_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","volume":"40","author":"T Restuccia","year":"2004","unstructured":"Restuccia T, Ortega R, Guevara M, Gin\u00e8s P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case\u2013control study. J Hepatol. 2004;40:140\u20136.","journal-title":"J Hepatol"},{"key":"389_CR41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.dld.2010.08.001","volume":"43","author":"P Caraceni","year":"2011","unstructured":"Caraceni P, Santi L, Mirici F, Montanari G, Bevilacqua V, Pinna AD, et al. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis. 2011;43:242\u20135.","journal-title":"Dig Liver Dis"},{"key":"389_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/MOT.0b013e3283614c7a","volume":"18","author":"E Sola","year":"2013","unstructured":"Sola E, Cardenas A, Gines P. Results of pretransplant treatment of hepatorenal syndrome with terlipressin. Curr Opin Organ Transplant. 2013;18:265\u201370.","journal-title":"Curr Opin Organ Transplant"},{"key":"389_CR43","first-page":"87","volume":"2","author":"P Angeli","year":"2010","unstructured":"Angeli P, Morando F. Optimal management of hepatorenal syndrome in patients with cirrhosis. Hep Med: Evidence Res. 2010;2:87\u20139.","journal-title":"Hep Med: Evidence Res"},{"issue":"Suppl 3","key":"389_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1478-3231.2011.02586.x","volume":"31","author":"D Hasper","year":"2011","unstructured":"Hasper D, Jorres A. New insights into the management of hepato-renal syndrome. Liver Int. 2011;31 Suppl 3:27\u201330.","journal-title":"Liver Int"},{"key":"389_CR45","doi-asserted-by":"crossref","unstructured":"Angeli P, Fasolato S, Cavallin M, Maresio G, Callegaro A, Sticca A, et al. Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical study. AASLD 2008: LB3","DOI":"10.1016\/S0168-8278(09)60177-X"},{"key":"389_CR46","doi-asserted-by":"publisher","unstructured":"Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62:567-74. doi: 10.1002\/hep.27709","DOI":"10.1002\/hep.27709"},{"key":"389_CR47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM199908053410603","volume":"341","author":"P Sort","year":"1999","unstructured":"Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-\u00c1rbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403\u20139.","journal-title":"N Engl J Med"},{"key":"389_CR48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cgh.2012.11.007","volume":"11","author":"F Salerno","year":"2013","unstructured":"Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol. 2013;11:123\u201330.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"389_CR49","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/hep.24786","volume":"55","author":"M Bernardi","year":"2012","unstructured":"Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials. Hepatology. 2012;55:1172\u201381.","journal-title":"Hepatology"},{"key":"389_CR50","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jhep.2013.07.020","volume":"59","author":"M Sim\u00f3n-Talero","year":"2013","unstructured":"Sim\u00f3n-Talero M, Garc\u00eda-Mart\u00ednez R, Torrens M, Augustin S, G\u00f3mez S, Pereira G, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study. J Hepatol. 2013;59:1184\u201392.","journal-title":"J Hepatol"},{"key":"389_CR51","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/cc6812","volume":"12","author":"M Jacob","year":"2008","unstructured":"Jacob M, Chappell D, Conzen P, Wilkes MM, Becker BF, Rehm M. Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials. Crit Care. 2008;12:R34.","journal-title":"Crit Care"},{"key":"389_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/ACO.0b013e32833724da","volume":"23","author":"F Polli","year":"2010","unstructured":"Polli F, Gattinoni L. Balancing volume resuscitation and ascites management in cirrhosis. Curr Opin Anaesthesiol. 2010;23:151\u20138.","journal-title":"Curr Opin Anaesthesiol"},{"key":"389_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ndt\/gfr736","volume":"27","author":"A Davenport","year":"2012","unstructured":"Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, Nadim MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012;27:34\u201341.","journal-title":"Nephrol Dial Transplant"},{"key":"389_CR54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0168-8278(03)00160-0","volume":"39","author":"K Brinch","year":"2003","unstructured":"Brinch K, M\u00f8ller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol. 2003;39:24\u201331.","journal-title":"J Hepatol"},{"key":"389_CR55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/hep.20766","volume":"42","author":"L Ruiz-del-\u00c1rbol","year":"2005","unstructured":"Ruiz-del-\u00c1rbol L, Monescillo A, Arocena C, Valer P, Gin\u00e8s P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439\u201347.","journal-title":"Hepatology"},{"key":"389_CR56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1478-3231.2008.01778.x","volume":"29","author":"P Tandon","year":"2009","unstructured":"Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, et al. The effect of 1\u00a0month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int. 2009;29:169\u201374.","journal-title":"Liver Int"},{"key":"389_CR57","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.26338","volume":"58","author":"R Garc\u00eda-Mart\u00ednez","year":"2013","unstructured":"Garc\u00eda-Mart\u00ednez R, Caraceni P, Bernardi M, Gin\u00e8s P, Arroyo V, Jalan R. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58:1836\u201346.","journal-title":"Hepatology"},{"key":"389_CR58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2110-5820-3-4","volume":"3","author":"M Taverna","year":"2013","unstructured":"Taverna M, Marie AL, Mira JP, Guidet B. Specific antioxidant properties of human serum albumin. Ann Intensive Care. 2013;3:4.","journal-title":"Ann Intensive Care"},{"key":"389_CR59","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0891-5849(01)00627-X","volume":"31","author":"R Marley","year":"2001","unstructured":"Marley R, Patel RP, Orie N, Ceaser E, Darley-Usmar V, Moore K. Formation of nanomolar concentrations of S-nitroso-albumin in human plasma by nitric oxide. Free Radic Biol Med. 2001;31:688\u201396.","journal-title":"Free Radic Biol Med"},{"key":"389_CR60","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/00365520902719273","volume":"44","author":"T-A Chen","year":"2009","unstructured":"Chen T-A, Tsao Y-C, Chen A, Lo G-H, Lin C-K, Yu H-C, et al. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol. 2009;44:619\u201325.","journal-title":"Scand J Gastroenterol"},{"key":"389_CR61","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/gut.2009.180570","volume":"59","author":"A Krag","year":"2010","unstructured":"Krag A, Bendtsen F, Henriksen JH, M\u00f8ller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105\u201310.","journal-title":"Gut"},{"key":"389_CR62","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1665-2681(19)31029-4","volume":"11","author":"A Umgelter","year":"2012","unstructured":"Umgelter A, Wagner KS, Reindl W, Luppa PB, Geisler F, Huber W, et al. Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1. Ann Hepatol. 2012;11:232\u20139.","journal-title":"Ann Hepatol"},{"key":"389_CR63","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/hep.26021","volume":"57","author":"A Bortoluzzi","year":"2013","unstructured":"Bortoluzzi A, Ceolotto G, Gola E, Sticca A, Bova S, Morando F, et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology. 2013;57:266\u201376.","journal-title":"Hepatology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-015-0389-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-015-0389-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-015-0389-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T18:26:35Z","timestamp":1567362395000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-015-0389-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,25]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1186\/s12876-015-0389-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,25]]},"article-number":"167"}}